Zydus Announces New Data Presentations at The Liver Meeting® 2022
Four Posters accepted at The Liver Meeting® 2022 Two Posters are awarded the “AASLD Presidential Poster Of Distinction” Ahmedabad, India November 03, 2022 Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), a discovery-driven, global lifesciences company
Four Posters accepted at The Liver Meeting® 2022
Two Posters are awarded the “AASLD Presidential Poster Of Distinction”
Ahmedabad, India November 03, 2022
Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), a discovery-driven, global
lifesciences company today announced that four abstracts on Saroglitazar Mg will be presented at
The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in
Washington, DC (November 4 – 8, 2022).
Presentation Details
Title: “Saroglitazar Improves Atherogenic Risk in Patients with Nonalcoholic Fatty Liver
Disease: Pooled Analysis from Randomized Controlled Trials” [Publication Number:
2598]
Title: “Saroglitazar versus Vitamin E in patients with biopsy proven NASH: a randomised
controlled trial” [Publication Number: 2390]
Title: “Safety and efficacy of saroglitazar in potential voluntary live liver donors with mild
to moderate hepatic steatosis. A single-centre experience” [Publication Number: 2509]
Title: “Saroglitazar in Nonalcoholic Steatohepatitis patients-a speck of optimism”
[Publication Number: 2396]
The Liver Meeting Digital Experience™ 2022 website has the full list of abstracts
[https://www.aasld.org/the-liver-meeting].
About Saroglitazar in Primary Biliary Cholangitis (PBC) and Non-alcoholic Steatohepatitis
(NASH)
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical
trial in patients with Primary Biliary Cholangitis (PBC) and Phase 2b in patients with Nonalcoholic Steatohepatitis (NASH).
The USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar
Mg for PBC. The European Medicines Agency (EMA) has designated “Saroglitazar magnesium”
with Orphan status for Treatment of Primary Biliary Cholangitis.
NASH is a chronic liver disease characterised by fat accumulation and inflammation in the liver,
which can progress to liver cirrhosis, need for liver transplant or death. There are currently no
drugs approved in the USA for treatment of NASH – a global unmet medical need.
